Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Lilly’s Jonsson to Stay as PhRMA Japan Chief
December 13, 2018
- 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018
- JPMA Chief Warns against Japan Govt’s Short-Sighted Budgeting, Calls for Longer-Term View on Innovation
November 26, 2018
- 8 Infectious Disease-Related Societies Launch New Organization to Combat Drug-Resistance Problem
November 12, 2018
- 7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey
November 9, 2018
- Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns
November 6, 2018
- Japan, US, Europe Trade Groups Stress Importance of Drug Discovery, Call for “Angel Cycle”
November 5, 2018
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
- EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman
October 16, 2018
- Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
October 15, 2018
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
- Generic Use Rate at 72.2% in April-June: JGA
October 1, 2018
- October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
September 25, 2018
- 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
September 18, 2018
- Think Tank Led by Ex-Pfizer Japan Chief to Compile Proposal on “100-Year Life” by Year-End
September 5, 2018
- Bayer Yakuhin Chief Prinz Named Vice Chairman of EFPIA Japan
September 3, 2018
- Ex-Pfizer Japan Chief Umeda to Now Helm Advocacy Group
August 29, 2018
- Over Half of Companies Control Supply of Off-Label Information: Ihoken Survey
August 27, 2018
- Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…